Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate

References

• O'Brien SG, Guilhot F, Goldman JM, et al International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 2008;112: Abstract 186.
   Web of Science ®Google Scholar
• Baccarani M, Saglio G, Goldman JM, et al Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of European Leukemia Net. Blood 2006;108:1809–1820.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network CML Guidelines V.2.2010; Available from: http://www.nccn.org [cited 25 August 2009].
   Google Scholar
• de Lavallade H, Apperley JF, Khorashad JS, et al Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358–3363.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin AS, et al Molecular and chromosomal mechanisms of resistance to imatinib (STI 571) therapy. Leukemia 2002;16:2190–2196.
   PubMed Web of Science ®Google Scholar
• Donato NJ, Wu JY, Stapley J, et al Imatinib mesylate resistance through bcr abl independence in chronic myeloid leukemia. Cancer Res 2004;64:672–677.
   PubMed Web of Science ®Google Scholar
• Shah NP, Nicoll JM, Nagar B, et al Multiple BCR ABL kinase domain mutations confer polyclonal resistance to tyrosine kinase inhibitor imatinib mesylate in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117–125.
   PubMed Web of Science ®Google Scholar
• Willis S, Lange T, Demehri S, et al High sensitivity detection of BCR ABL kinase domain mutations in imatinib naive patients: correlation with clonal cytogenetic evolution but not with response to therapy. Blood 2005;106:2128–2137.
   PubMed Web of Science ®Google Scholar
• Zonder JA, Pemberton P, Brandt H, Mohmad AN, Schiffer CA. The effect of dose increase to imatinib mesylate with chronic or accelerated phase chronic myeloid leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2002;9:2092–2097.
   Web of Science ®Google Scholar
• Marin D, Goldman JM, Olavarria E, Apperly J. Transient benefit only from increasing the matinib dose in CML patients who do not achieve cytogenetic remissions on conventional doses. Blood 2003;102:2702–2703.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Talpaz M, O Brien S, et al Dose escalation of imatinib mesylate can overcome resistance to standard dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101:473–475.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian M, Jones D, et al Imatinib dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard dose imatinib therapy. Blood 2009;113:2154–2160.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Hamerschlak N, et al Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007;109:5143–5150.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al Efficacy and safety of a specific inhibitor of BCR ABL tyrosine kinase in chronicmyeloid leukemia. New Eng J Med 2001;334:1031–1037.
   Web of Science ®Google Scholar
• Talpaz M, Silver RT, Druker BJ, et al Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928–1937.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, La Rosee P. Imatinib therapy in chronic myeloid leukemia: strategies to avoid and overcome resistance. Leukemia 2004;18:1321–1331.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawers C, Hochhaus A, et al Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New Eng J Med 2002;346:645–652.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Eide C, Deninger M, et al BCR ABL kinase domain mutations, drug resistance and the road to a cure for chronic myeloid leukemia. Blood 2007;110: 2242–2249.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Jones D, et al Frequency and clinical significance of BCR ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006;20:1767–1773.
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S, et al Detection of BCR ABL mutations in patients with CML is virtually always accompanied by clinical resistance and mutations in the ATP phosphate binding loop (P-loop) are associated with poor prognosis. Blood 2003;102:276–283.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Rousselot P, Pasquini R, et al Dasatinib or high dose imatinib for patients with chronic phase chronic myeloid leukemia resistant to standard dose imatinib: a 2 year follow up from the START-R (CA-180-017). Blood 2007;110(Suppl.): 226a (Abstract 736).
   Google Scholar